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Abstract 
More than 25 million people have diabetes in the United States and its complications make it a leading 
cause of death. Pacific Islanders, specifically Micronesians, experience even higher rates of diabetes, and 
pharmacist care for these individuals may improve health outcomes. Objective: To better address health 
disparities in this population, a health center serving Hawaii Island added clinical pharmacy services into 
their shared medical appointment program for diabetes management. Methods: Standard care (n= 21) 
consisted of weekly education sessions for patients provided by a multi-disciplinary team, after which 
patients had one-on-one appointments with a primary care provider if they met threshold clinical criteria. 
The intervention group (n=36) received the same services, plus a medication management service 
provided by a pharmacist during the one-on-one appointments. Results: There was no statistically 
significant difference between the pharmacist care and standard care groups on clinical measures 
including glycosylated hemoglobin, low density lipoprotein and blood pressure at the end of the eighteen-
month intervention period. Conclusion: Pacific Islanders face unique health care challenges including 
low socioeconomic status, language barriers and differences in cultural perceptions of health care. The 
value of clinical pharmacy has been well-documented in the literature but further study of the role and 
impact of these services is warranted for high-risk populations. 
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Introduction 
 
More than 25 million people, or 8.3% of the 
United States population, have diabetes. 
Diabetic complications are the seventh leading 
cause of death in the United States (Centers for 
Disease Control and Prevention, 2011), and the 
fifth leading cause of death among Asian 
American and Pacific Islanders (AAPI) (Centers 
for Disease Control and Prevention, 2012). The 
limited information that is available regarding 
Pacific Islanders from Micronesia suggests that 
they suffer disproportionately from diabetes, 
partially due to their high rates of obesity 
(Curtis, 2004; Davis et al., 2004; Lee et al., 
2007; Stark, Niederhauser, Camacho, & Shirai, 
2011). This high-risk subgroup has rarely been 
included in clinical studies despite the fact that 
they are the one of the fastest growing AAPI 
subpopulations (2010 Census). 
 
Shared Medical Appointments 
The epidemic rate of diabetes is prompting the 
medical community to face care gap challenges 
in ways that will maximize treatment efficiency 
and effectiveness, while containing costs. One 
approach that is being implemented is the 
Shared Medical Appointment (SMA) model 
(Bendex & Bower, 2011). SMAs differ from the 
traditional medical appointment in that a multi-
disciplinary team consisting of a primary health 
care provider (e.g. physician, nurse practitioner, 
physician assistant) along with support staff 
including a pharmacist, nurse, medical assistant, 
and other facilitators (e.g., a social worker, a 
psychologist, a dietician, etc.) sees a group of 
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patients at the same time in an extended 
appointment. There are several models for 
SMAs including the drop-in group medical 
appointment (DIGMA), physical shared medical 
appointment (PSMA) and cooperative health 
care clinics (CHCC). This study used the CHCC 
model, which consists of a group education and 
support session followed by an individual 
session with the primary care provider and 
support team (Bendix & Brower, 2011; 
Weinger, 2003).  
 
At a time when the country is grappling with the 
primary care shortage, seeing several patients 
together has the potential to improve access to 
care, decrease heath care costs and increase care 
efficiency. In addition, the support from other 
fellow SMA patients and educational 
components from group sessions may also 
improve patient adherence and outcomes 
(Bendix & Brower, 2011; Edelman et al., 2010; 
Schmucker, 2006). These factors may be 
especially beneficial for bridging the health care 
gap for Micronesians through increasing shared 
social support and health literacy. 
 
There is limited information regarding the 
efficacy of SMAs in diabetes care, and what 
information is available is inconsistent. Some 
studies have shown minimal impact on clinical 
outcomes such as glycosylated hemoglobin 
(A1c), cholesterol and blood pressure (Clancy, 
Huang, Okonofua, Yeager, & Magruder, 2007; 
Edelman et al., 2010) while others have shown 
an improvement in glycemic control (Desouza, 
Rentschler, & Haynatzki, 2010; Pringle et al., 
1993; Trento et al., 2001), and increases in 
preventive procedures, screenings, and patient 
education (Wagner et al., 2001). 
 
Role of Pharmacists in Shared Medical 
Appointments 
The estimated rate of non-adherence to diabetes 
medications is between 36 to 93% (Bailey & 
Kodack, 2011; Nair, Miller, Park, Allen, Saseen 
& Biddle, 2010; Rosenfield, Hunt, Plauschinat, 
& Wong, 2008). Pharmacists may enhance the 
quality of care provided in a SMA setting 
through provision of patient education regarding 
medications, as well as the disease state itself, 
nutrition, exercise, adherence and other 
components of comprehensive diabetes care. 
Information on the role and impact of 
pharmacist involvement in SMAs is sparse, but 
available information is positive, with 
pharmacist care improving glycemic control, 
lipid levels and blood pressure for intervention 
groups (Cohen et al., 2011; Kirsh et al., 2007; 
Taveira et al, 2010; Taveira, Dooley, Cohen, 
Khatana, & Wu, 2011).  
 
The purpose of this retrospective study is to 
evaluate the impact of clinical pharmacist care 
as part of a multidisciplinary SMA model 
delivering diabetes care for Micronesians as 
compared to a control SMA model that did not 
include pharmacist care. We predicted that 
pharmacist care would enhance the quality of 
diabetes care in a team approach and 
subsequently improve diabetes clinical health 
indicators in our study population. Not only does 
this information increase awareness of the role 
of pharmacists in SMA models of care, but also 
demonstrates the potential impact of pharmacist 
care for high-risk populations such as Pacific 
Islanders. 
 
Methods 
 
Study Design 
In response to the diabetes epidemic, Hilo Bay 
Clinic, Inc. (BCI) piloted two SMA diabetes 
groups in 2006, one consisting of Chuukese 
patients and one of Marshallese patients, each 
SMA with separate translators for the two 
languages. The program had open enrollment, 
regardless of level of diabetes control. At the 
end of the trial period, those enrolled showed 
significant improvements in measured health 
indicators such as A1c and blood pressure 
(unpublished). 
 
In January 2011, a clinical pharmacist on faculty 
at the University of Hawaii, The Daniel K. 
Inouye College of Pharmacy joined the diabetes 
multidisciplinary care team. Based on random 
assignment, the pharmacist provided medication 
therapy management services to the Marshallese 
SMA diabetes group. This intervention was 
compared to the standard care group, consisting 
of the Chuukese SMA diabetes group who did 
not receive additional clinical pharmacy 
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services. The multidisciplinary standard care 
team consisted of a nurse practitioner, diabetes 
educator, dietician and translator. 
 
Clinical Pharmacy Service Description 
Group Sessions. The SMA diabetes program 
involved weekly group sessions taught by a 
registered dietician, certified diabetes educator 
or a registered nurse at BCI. Ten American 
Diabetes Association education standard topics 
were covered in one to two hour sessions over a 
revolving six-week course. However, the 
program had open enrolment and the vast 
majority of patients continued to attend weekly 
SMA sessions and appointments even after 
completing the course. The intervention group 
also received education workshops conducted by 
the pharmacist and student pharmacist during 
the intervention period. Pharmacist-led sessions 
occurred every six weeks and included 
interactive presentations and education on 
diabetes pathophysiology and complications, 
medications, value of adherence and other 
components of comprehensive diabetes care. 
There was significant emphasis placed on topics 
such as refill education and appropriate 
medication use, with multiple sessions focusing 
on obtaining individual patients’ pharmacy 
information and designing and translating 
patient-specific monthly refill instruction sheets 
and protocols. Based on prior and ongoing 
feedback, presentation topics and interactive 
workshops were tailored to cultural differences 
in care needs. 
 
Individual Sessions. After each group session, 
SMA patients continued on to an individual 
appointment with the primary care team based 
on screening performed during the group session 
and/or patient choice. Abnormal weight, point-
of-care glucose and blood pressure readings 
triggered a same-day referral to individual 
appointment, as well as any new diabetes care 
issues reported by the patient or ongoing 
diabetes related concerns requiring follow-up. 
There was no cap to the number of patients who 
were seen for same-day individual 
appointments. The primary care provider and the 
clinical pharmacist saw the patient during the 
individual sessions and treatment plans were 
developed together at the point of care. 
The clinical pharmacist evaluated the patient and 
made medication therapy recommendations 
including initiation, discontinuation and dose-
titration of diabetes, hypertension and 
dyslipidemia medications. In addition, the 
pharmacist provided diabetes education, 
including nutrition and exercise management, 
blood glucose monitoring and hypoglycemia 
care education, and medication and adherence 
counseling during the appointment. The 
pharmacist also resolved any insurance and 
formulary discrepancies, provided pillbox filling 
and education services and responded to refill 
requests from both patients and pharmacies.  
 
Patients 
All patients enrolled at any point in the BCI 
Diabetes Self-Management Education (DSME) 
program between January 2011 and June 2013 
were included in the study. The Marshallese 
group had 39 enrollees but three individuals 
were not included in the analysis as they did not 
have a diagnosis of diabetes. The Chuukese 
group had 21 enrollees; all were included in the 
analysis. The majority of patients enrolled in the 
program received Medicaid benefits and had an 
annual income of less than $20,000. 
Additionally, most of the patients were non-
English speaking and communication was 
provided by translator services. Data on 
adherence rates to the program were not 
collected for this study, however it was noted by 
the SMA team that participants oftentimes had 
poor follow-up rates. 
 
Outcomes 
The primary outcomes, all components of 
comprehensive diabetes care, included the 
clinical health indicators of A1c, low-density 
lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), triglycerides 
(TG), total cholesterol (TC), body mass index 
(BMI) and blood pressure (both systolic and 
diastolic) (American Diabetes Association, 
2014). These indicators, if available, were 
collected at baseline and quarterly every three 
months, over a period of 18 months. Baseline 
information was collected for the fourth quarter 
of 2010 prior to the integration of clinical 
pharmacy services for the intervention group. 
Data from the fourth quarter of 2010 was 
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considered baseline for the control group. If no 
data was available during this period then the 
most recent data going backwards in time was 
considered baseline.  
 
Data Collection 
Patient data from SMA with pharmacist 
(intervention group, n=36) and SMA without 
pharmacist (control group, n =21) was collected 
retrospectively from patient charts and the 
electronic medical record (BCI transitioned from 
paper charts to electronic medical records during 
the data collection period).  
 
Statistical Analysis 
Observational retrospective analysis of diabetes 
health outcome indicators was conducted to 
evaluate the impact of a clinical pharmacist in 
the intervention arm as compared to the standard 
care arm. Fischer’s exact test for categorical 
variables and t-tests for continuous variables 
were used to examine whether there were 
statistically significant differences in patient 
characteristics and clinical health indicators 
between the intervention and standard care 
groups at baseline. 
 
To examine whether the intervention impacted 
changes in clinical health indicators for the 
invention group relative to the control group, we 
used a difference in difference approach 
utilizing a linear regression model (i.e., change 
in health indicator for the intervention group 
versus change in health indicator for the control 
group). In a second model, we adjusted for BMI 
which was the only patient characteristic that 
differed significantly between groups. The study 
was approved as exempt by the University of 
Hawaii Institutional Review Board (IRB). 
 
Results 
 
Baseline Health Characteristics and Health 
Indicators  
Baseline patient health characteristics were 
similar between the two groups except for rates 
of obesity, which were significantly higher in 
the Chuukese group (standard care) at 80% 
compared to 43% (p=0.006) in the Marshallese 
group (intervention) (Table 1). Furthermore, the 
Marshallese group trended towards a higher A1c 
(Table 2). Overall, 70% had hypertension, 71% 
had dyslipidemia and 13% had cardiovascular 
disease. On average, A1c was 8.8%, LDL 
cholesterol was 105.5 mg/dL, HDL cholesterol 
was 37.5 mg/dL and triglycerides were 159 
mg/dL. 
 
Patients took an average of 4.4 medications, 
with no differences between the two groups in 
number of medications taken for diabetes, 
hypertension and dyslipidemia
Table 1 
 
Baseline Health Characteristics for Intervention and Standard Care Arms 
 Overall (n=57) Intervention (n=36) Standard Care (n=21) p 
Age [Mean (SD)] 56.8 (1.1) 56.0 (1.6) 58.1 (1.9) 0.39 
Obese (BMI >30)  (%) 57.1 42.9 81.0 0.006* 
Current smoker (%) 7.3 2.9 14.3 0.15 
Former smoker (%) 21.8 20.6 23.8 1.0 
Hypertension (%) 69.6 65.7 76.2 0.55 
Dyslipidemia (%) 71.4 80.0 57.1 0.13 
Coronary artery disease (%) 12.5 8.6 19.0 0.41 
Stroke (%) 5.4 8.6 0 0.28 
Condition count [Mean (SD)] 4.4 (0.3) 4.6 (0.3) 4.0 (0.6) 0.34 
Number of medications (total) 4.4 (0.3) 4.5 (0.4) 4.3 (0.5) 0.75 
   Diabetes 1.5 (0.1) 1.5 (0.2) 1.4 (0.2) 0.73 
   Hypertension 1.0 (0.1) 0.9 (0.2) 1.1 (0.2) 0.68 
   Dyslipidemia 0.8 (0.1) 0.9 (0.1) 0.7 (0.1) 0.24 
Diabetes medications (%) 
   Metformin 69.1 65.7 75.0 0.55 
   Sulfonylurea 30.9 34.3 35.0 0.55 
   DPP4 Inhibitor 1.8 2.9 0.0 1.0 
   Insulin 30.9 31.4 30.0 1.0 
p-value <0.05     
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Table 2 
 
Clinical Health Indicators for Intervention and Standard 
Care Arms at Baseline 
 Overall 
(n=57) 
Interventi
on  (n=36) 
Standard 
Care  
(n=21) 
p 
Weight [Mean 
Kg (SD)] 83.1 (2.6) 77.9 (3.2) 92.0 (3.5) 0.007* 
Body Mass 
Index (BMI) 32.6 (0.96) 30.7(1.1) 35.8(1.6) 0.009* 
A1c 8.8 (0.3) 9.1 (0.4) 8.3 (0.3) 0.16 
LDL 105.5 (.48) 105.2 (6.0) 106.0 (8.2) 0.93 
HDL 37.5 (0.9) 37.8 (1.3) 37.0 (1.3) 0.63 
Total 
Cholesterol 172.6 (5.7) 
175.7 
(7.6) 167.5 (8.7) 0.49 
Triglycerides 159.4 (15.5) 173.5 (22.7) 
135.9 
(16.3) 0.25 
Systolic 
Blood 
Pressure 
127.3 (2.7) 126.8 (3.7) 128.3 (3.8) 0.78 
Diastolic 
Blood 
Pressure 
76.4 (1.3) 77.2 (1.5) 74.9 (2.7) 0.40 
p-value <0.05 
 
Clinical Health Indicator Outcomes 
There were no statistically significant difference-in-
difference changes found between the intervention and 
standard care groups for any of the clinical health 
indicators including A1c, LDL and blood pressure at 
baseline and 18-month follow-up (Table 3), with and 
without adjustment, for BMI. The control group trended 
towards more weight loss than the intervention group, 
but the results did not reach statistical significance. 
There were fluctuations in A1c and LDL within the 18-
month follow-up period but there was no difference at 
the end of the study period. 
 
Discussion 
 
This study evaluated the potential impact of the addition 
of a clinical pharmacist into a SMA model of care for 
Micronesians with diabetes. There were no differences 
seen in clinical health indicators between the 
intervention arm receiving clinical pharmacist care and 
the standard care arm at the end of the 18-month study 
period, even when adjusted for BMI. 
 
Table 3 
 
Change in Health Indicator Measures for Intervention and Control Groups and 
Difference-In-Difference Estimate 
  Baseline 
(Q4 2010) 
Follow-up 
(Q1/Q2 
2012) 
Change 
(Follow-up 
– Baseline) 
Difference- 
in- 
Difference 
p-value 
adjusted 
for BMI 
Body Mass 
Index (BMI) 
Intervention 30.9 30.3 -0.6 3.9 NA 
Control 35.8 31.3 -4.5 
HbA1C Intervention 9.1 8.7 -0.4 -0.5 0.49 Control 8.3 8.5 0.2 
LDL Intervention 105.2 117.8 12.6 11.0 0.45 Control 106.1 107.6 1.5 
HDL Intervention 37.8 40.8 3.0 3.6 0.19 Control 37.0 36.3 -0.7 
Total 
Cholesterol 
Intervention 175.7 186.5 10.8 14.2 0.35 
Control 167.5 164.1 -3.4 
Triglycerides Intervention 173.5 139.6 -33.9 0.5 0.85 Control 135.9 101.5 -34.4 
Systolic Blood 
Pressure 
Intervention 126.8 129.1 2.3 0.9    0.76 
Control 128.3 129.7 1.4 
Diastolic Blood 
Pressure Intervention 
77.2 77.2 0 -0.3 0.90 
 
Diabetes is a growing epidemic nationally and Native 
Hawaiians and Pacific Islanders (NHPI) suffer 
disproportionately from the condition with it being two 
to four times more prevalent in NHPI than the general 
population (American Diabetes Association, n.d.; Mau, 
Sinclair, Saito, Baumhofer, & Kaholokula, 2009; Moy, 
Sallis, & David, 2010; Wergowske & Blanchette, 2012). 
Due to their small population size NHPI are typically 
evaluated together in studies, although it is important to 
examine subpopulations since differences exist between 
rates of obesity, health status and healthcare access 
(Juarez, Samoa, Chung, & Seto, 2010). For instance, we 
know that obesity rates are higher in Chuukese and 
Marshallese than other NHPI subpopulations (Davis et 
al., 2004; Lee et al., 2007; Stark, Niederhauser, 
Camacho, & Shirai, 2011). Despite the Chuukese 
population growing by six times and Marshallese 
population growing by three times in the United States 
between 2000 and 2010 (2010 Census), little is known 
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about the health and health care of this NHPI cohort with 
available information pointing to high levels of health 
disparities and poor health status (Moy, Sallis, & David, 
2010, US General Accounting Office, 2001, Wergowske 
& Blanchette, 2012). SMAs are becoming a popular, 
nontraditional approach to managing high risk 
populations and multidisciplinary programs such as the 
one described which include clinical pharmacist care 
may improve health outcomes for these individuals. 
 
While information regarding the role of pharmacist care 
in SMA models is scarce, the impact of clinical 
pharmacist care on diabetes outcomes has been well-
documented in the literature (Cranor, Bunting, & 
Christensen, 2003; Fera, Bluml, & Ellis, 2003; Machado, 
Bajcar, Guzz, & Einarson, 2007). Recently, The 
Diabetes Initiative Program showed that collaboration 
between pharmacists and primary care physicians 
significantly decreased glycosylated hemoglobin (A1c) 
by 1.16% over a one-year period (p<0.0001). 
Collaborative methods included several designs 
involving either independent prescribing by the 
pharmacist under collaborative practice agreement, dual 
physician-pharmacist appointments or independent 
pharmacist visits followed by consult with the physician 
(Farland, et al., 2013). In a health maintenance 
organization (HMO), inclusion of a pharmacist into 
primary care teams significantly reduced A1c by 2.6% as 
compared to control groups without pharmacist care 
over one -year (p<0.001). Projected long-term 
cardiovascular risk was also significantly decreased in 
the intervention arm receiving pharmacist care. In this 
model, uncontrolled diabetics with A1c ≥7% were 
referred by the primary care team to the pharmacist for 
more stringent follow-up; the pharmacist performed 
pharmacotherapy adjustments under collaborative 
practice agreement (Ip et al., 2013).  
 
While our pilot program did not find a significant 
improvement in A1c between the pharmacist care and 
standard care groups, further study is still warranted to 
evaluate the role of pharmacist care in unique delivery 
models with high-risk patient population such as the one 
studied.  
 
Lessons Learned 
There were several notable unique challenges to 
providing quality care for this Micronesian cohort that 
may need to be taken into account when planning future 
pilot programs.   
 
Transportation Barriers. Data for SMA program 
attendance was not collected, but it was observed that 
the program experienced significant rates of poor patient 
follow-up due to several reasons. Rural communities 
often experience unique health care barriers such as 
difficulty making follow-up appointments and classes 
due to challenges in obtaining transportation. This 
barrier to care was documented extensively in annual 
program evaluations completed by the patients in both 
study arms.  
 
Health Literacy Barriers. While primary school 
enrollment rates in the Pacific Islands are high, access to 
secondary school is low, with data showing only 20% of 
children completing secondary education in one Pacific 
Island nation (Kidd, 2012). Even if children attend 
school, the quality of education may not be adequate to 
provide them an advantage in the labor market, and 
much less health literacy (Kidd, 2012). Our non-
significant findings may indicate that the health 
education delivered may need to be modified to impact 
the study population more meaningfully. 
 
Travel Barriers. Many Micronesians in the program 
took extended leave for months at a time to visit 
Micronesia. During these periods, they were often 
unable to obtain their chronic disease state medications, 
including those for diabetes.  
 
Medication Refill Barriers. Medication refills were a 
particular challenge. Refill rates were not documented in 
the study, but significant amount of pharmacist time 
were spent educating on the value of refills as well as 
how to obtain a refill. All Micronesian patients are 
eligible for Medicaid in the United States. Even though 
they do not pay a medication co-payment, yearly 
changes to the formulary, which affect what medications 
are available, may have a significant impact on patient 
adherence in this population with poor health literacy. 
When medication changes were made to accommodate 
formularies, it was noted by the health care team that 
poor fill rates occurred. This may have been due to 
multiple reasons including unclear understanding of the 
medications, language barriers and transportation 
difficulties. A formal and structured approach to refill 
education may be warranted to enhance adherence in the 
future. 
 
Study Design Barriers. The program may have limited 
its own efficacy due to its design. The large SMA group 
size increased wait times to see the primary care team 
after the initial education session. These wait times 
could be nearly three to four hours long in the 
intervention arm as compared to shorter wait times in the 
smaller standard care arm. The limiting factor was 
translator services since only one patient could be seen at 
a time, given the language barrier. While not 
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documented, many patients who were unable or 
unwilling to wait for their one-on-one appointment left 
prior to being seen. Additionally, those who were seen 
individually had limited amount of time with the 
pharmacist for one-on-one education. In this population 
with low literacy, expanding individual appointment 
time by increasing translation services may be critical to 
improving health outcomes.  
 
Limitations and Future Directions 
We conclude that our lack of significant findings in this 
study may be due to multiple limitations including study 
design, program design and challenges to care in this 
unique population. Our study was limited by its 
retrospective nature and small sample size; future 
directions include prospective analysis of larger 
population cohorts, as well as controlling for potential 
confounding factors involved with differences in 
ethnicity and cultural backgrounds. Streamlining 
programs to decrease wait times may aid in improving 
adherence and attendance, evaluation of the program 
with consistent health care follow-up may alter results. 
Additionally, increasing access and care time spent with 
the pharmacist in medication and disease state 
counseling and education may enhance patient 
understanding and improve both adherence and 
involvement in their own health care. Finally, tailored 
interventions that address other unique health care 
challenges in these patient populations, such as language 
barriers, physical access to care and differences in 
cultural perception of health and health care are critical. 
Pharmacists involved in such programs may undergo 
training programs to enhance their cultural sensitivity 
and awareness as well. 
 
As the nationwide diabetes epidemic grows, the medical 
community must find innovative and effective solutions 
to address patient care needs. These efforts may show 
that pharmacist-directed care, within SMA models, 
improves patient outcomes in underserved populations. 
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